Trial Profile
A phase 2 proof-of-concept trial in the orphan tauopathy disease progressive supranuclear palsy (PSP) in elderly patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2017
Price :
$35
*
At a glance
- Drugs ASN 90 (Primary)
- Indications Progressive supranuclear palsy
- Focus Proof of concept; Therapeutic Use
- 13 Apr 2017 New trial record
- 06 Apr 2017 This trial is expected to begin in 2018, according to an Asceneuron media release.